Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.
Exceptional growth potential with flawless balance sheet.
Share Price & News
How has Catalyst Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CN2's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CN2 exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: CN2 exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Catalyst Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Catalyst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CN2 (€4.7) is trading below our estimate of fair value (€9.96)
Significantly Below Fair Value: CN2 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CN2 is poor value based on its PE Ratio (56.7x) compared to the Biotechs industry average (39.7x).
PE vs Market: CN2 is poor value based on its PE Ratio (56.7x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: CN2 is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: CN2 is overvalued based on its PB Ratio (6.9x) compared to the DE Biotechs industry average (3.5x).
How is Catalyst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CN2's forecast earnings growth (31.3% per year) is above the savings rate (-0.4%).
Earnings vs Market: CN2's earnings (31.3% per year) are forecast to grow faster than the German market (13.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CN2's revenue (21.5% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: CN2's revenue (21.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CN2's Return on Equity is forecast to be very high in 3 years time (43.4%).
How has Catalyst Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CN2 has high quality earnings.
Growing Profit Margin: CN2 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CN2 has become profitable over the past 5 years, growing earnings by 0.7% per year.
Accelerating Growth: CN2 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CN2 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: CN2's Return on Equity (12.1%) is considered low.
Return on Assets
Return on Capital Employed
How is Catalyst Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CN2's short term assets ($90.6M) exceed its short term liabilities ($18.0M).
Long Term Liabilities: CN2's short term assets ($90.6M) exceed its long term liabilities ($725.7K).
Debt to Equity History and Analysis
Debt Level: CN2 is debt free.
Reducing Debt: CN2 has not had any debt for past 5 years.
Inventory Level: CN2 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CN2's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CN2 is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: CN2 is profitable, therefore cash runway is not a concern.
What is Catalyst Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CN2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CN2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CN2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CN2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CN2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pat McEnany (72yo)
Mr. Patrick J. McEnany, also known as Pat, Co-Founded Catalyst Pharmaceutical Partners Inc. in January 2002 and has been its Chairman and President since March 2006 and also its Chief Executive Officer sin ...
CEO Compensation Analysis
Compensation vs Market: Pat's total compensation ($USD3.46M) is above average for companies of similar size in the German market ($USD792.68K).
Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.
|COO & Chief Scientific Officer||9.1yrs||US$1.66m||0.64% $3.1m|
|Chief Medical Officer & Head of Regulatory Affairs||4.7yrs||US$1.67m||no data|
|VP, Treasurer & CFO||8.2yrs||US$523.85k||0.38% $1.9m|
|Chief Legal & Compliance Officer||4yrs||US$353.27k||no data|
|Senior Vice President of Sales & Marketing||1.5yrs||no data||no data|
|Chief Commercial Officer||1.7yrs||no data||0.0030% $14.7k|
|Corporate Secretary||0yrs||no data||no data|
|Consultant||0yrs||no data||no data|
Experienced Management: CN2's management team is considered experienced (4.7 years average tenure).
|Independent Director||17.3yrs||US$216.51k||0.21% $1.0m|
|Independent Director||17.3yrs||US$217.01k||0.30% $1.5m|
|Independent Director||5yrs||US$220.01k||0.22% $1.1m|
|Lead Independent Director||8.6yrs||US$238.51k||0.54% $2.6m|
|Independent Director||5yrs||US$211.01k||no data|
|Member of Scientific Advisory Board||0yrs||no data||no data|
|Member of Scientific Advisory Board||0yrs||no data||no data|
|Chairman of Scientific Advisory Board||0yrs||no data||no data|
|Member of Scientific Advisory Board||9.3yrs||no data||no data|
Experienced Board: CN2's board of directors are considered experienced (9.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
Catalyst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Catalyst Pharmaceuticals, Inc.
- Ticker: CN2
- Exchange: DB
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$529.662m
- Listing Market Cap: US$490.785m
- Shares outstanding: 103.05m
- Website: https://www.catalystpharma.com
Number of Employees
- Catalyst Pharmaceuticals, Inc.
- 355 Alhambra Circle
- Suite 1250
- Coral Gables
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CPRX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2006|
|CN2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2006|
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 22:02|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.